Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

21. Kang C, Han P, Lee J S, Lee D, Kim D. Anchor, Spacer, and Ligand-Modified Engineered Exosomes for Trackable Targeted Therapy. Bioconjugate chemistry. 2020; 31 : 2541-2552

22. Yoon S, Kim Y, Youn Y S, Oh K T, Kim D, Lee E S. Transferrin-Conjugated pH-Responsive γ-Cyclodextrin Nanoparticles for Antitumoral Topotecan Delivery. Pharmaceutics. 2020; 12

23. Lee E, Park J, Youn Y S, Oh K T, Kim D, Lee E S. Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis. Biomedicines. 2020; 8

24. Kang M, Tang B, Li J, Zhou Z, Liu K, Wang R, Jiang Z, Bi F, Patrick D, Kim D, Mitra A K, Yang-Hartwich Y. Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA. Molecular cancer. 2020; 19 : 143

25. Arun Kumar S, Good J, Hendrix D, Yoo E, Kim D, Deo K A, Jhan Y Y, Gaharwar A K, Bishop C J. Nanoengineered Light-Activatable Polybubbles for On-Demand Therapeutic Delivery. Advanced functional materials. 2020; 30 : 2003579

Grants

6. Preclinical assessment of exosomal drug delivery system using innovative tumor mouse model. Misc Non-Federal. Start Date: 2024. End Date: 2024.

7. Role of Renal Lymphatics in Blood Pressure Regulation. NIH. Start Date: 2018. End Date: 2023.

8. Cancer exosome mediated antibody production for active tumor targeting treatment. Non-federal. Start Date: 2022. End Date: 2023.

9. Engineering Exosome for Ovarian Cancer Targeting Therapy. NIH. Start Date: 2021. End Date: 2023.

10. Exosome based intraocular therapy combined with active targeting of ocular neovascularization. NIH. Start Date: 2022. End Date: 2022.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results